Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis

Ruiqiu Zhao, Xiaoru Long, Jiangxia Wang, Jing Zhu, Cong Liu, Tingting Shang, Zhenzhen Zhang, N Engels, Lynda Osadebe, Yue Kang, Jie Liu, Xiaodi Chen, Hongmei XuFrontiers in Pediatrics 2022 · DOI

TL;DR

This systematic review and meta-analysis evaluates the effectiveness and safety of ertapenem for treating infections in children. The findings suggest ertapenem is a viable option, showing similar efficacy and safety profiles compared to beta-lactam antibiotics, though further large-scale comparative studies are needed to solidify these conclusions.

What Problem Does This Paper Address?

Bacterial infections are a significant health concern for children, leading to serious consequences and even mortality. While antibiotics are crucial for treatment, the unique physiology of children (e.g., different drug metabolism and tolerance) necessitates careful consideration of antibiotic choices. Ertapenem, a carbapenem antibiotic with a once-daily dosing regimen, has been used for various infections, but most evidence on its effectiveness and safety has focused on adults. There was a clear need for a comprehensive review specifically examining its use in pediatric populations to inform clinical practice and optimize antibiotic stewardship.

Methods

The researchers conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. They systematically searched eight major biomedical databases (Web of Science, Embase, PubMed, Cochrane Library, CBM, CNKI, VIP, and Wanfang) to identify relevant studies. The primary outcome of interest was the treatment success rate, with secondary outcomes including adverse events, length of hospital stay, and mortality. For quantitative synthesis, they used random-effect models to estimate risk ratios (RRs) and 95% confidence intervals (CIs). Subgroup analyses were performed to explore potential sources of heterogeneity and to investigate differences based on patient demographics (Asian vs. non-Asian), infection sites, and comparator antibiotic classes. The quality of included studies was assessed using the Cochrane Risk of Bias tool for RCTs and the Newcastle-Ottawa Scale for observational studies.

Datasets

Not discussed in the paper. The paper focuses on synthesizing data from existing published studies.

Key Insights and Ideas

  • Ertapenem holds its own against established treatments: The study provides robust evidence that ertapenem is as effective as traditional beta-lactam antibiotics for treating common childhood infections. This is crucial for clinicians looking for reliable alternatives.
  • Safety profile is reassuring: Importantly, ertapenem did not appear to increase the risk of overall adverse events, drug-related diarrhea, or injection site pain compared to beta-lactam antibiotics. This is a significant finding for a class of antibiotics that can sometimes raise safety concerns.
  • Once-daily dosing is a practical advantage: While not explicitly a "finding" of the meta-analysis itself, the paper highlights ertapenem's once-daily administration as a key benefit, offering convenience for both patients and caregivers, especially in pediatric settings where adherence can be challenging.
  • Evidence base is still developing: Despite the meta-analysis, the authors acknowledge that the evidence, particularly for specific outcomes and subgroups, is based on a limited number of studies with relatively small sample sizes. This points to the need for more research.

Key Results

The meta-analysis included 15 studies involving 2,528 pediatric patients.

  • Treatment Success Rate: Ertapenem demonstrated a similar treatment success rate compared to beta-lactam antibiotics (RR = 1.08, 95% CI: 0.99-1.19).
  • Adverse Events:
    • No significant difference was found in the risk of any adverse events (RR = 1.02, 95% CI: 0.71-1.48).
  • Similarly, no increased risk of drug-related diarrhea (RR = 0.62, 95% CI: 0.31-1.25) or injection site pain (RR = 1.66, 95% CI: 0.59-4.68) was observed when compared to beta-lactam antibiotics.
  • Subgroup Analysis: No significant differences in efficacy or safety were found when comparing ertapenem to other carbapenems or when analyzing data from Asian versus non-Asian children. The site of infection also did not appear to impact these comparisons.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small Sample Sizes and Wide CIs: The meta-analysis, while informative, often relied on a small number of studies for specific outcomes, leading to wide confidence intervals and imprecise estimates. This limits the definitive conclusions that can be drawn.
  • Heterogeneity: Potential heterogeneity across studies in terms of patient populations, interventions, and control groups could influence the results.
  • Publication Bias: The inclusion of non-randomized controlled trials alongside RCTs may have lowered the overall quality of evidence.
  • Insufficient Evidence for Specific Scenarios: The authors noted insufficient evidence for the use of ertapenem in certain contexts, such as treating CAP, cIAI, and cUTI in Asian populations, and for comparisons with specific antibiotic combinations.

Future work should focus on conducting larger, well-designed randomized controlled trials to provide more definitive evidence. Specific areas for future research include:

  • Direct comparisons of ertapenem with other commonly used antibiotics in children, such as piperacillin-tazobactam or cefoperazone-sulbactam.
  • Investigating the effectiveness and safety of ertapenem for less common but serious infections like bloodstream infections, biliary tract infections, infectious endocarditis, and gastrointestinal infections.
  • Evaluating the cost-effectiveness of ertapenem treatment in pediatric populations.
  • Further exploring optimal dosing and duration strategies tailored to specific pediatric diseases.

Summary updated

Abstract

Our findings suggest that ertapenem is effective and safe in treatment for children with infection. Further comparative real-world data is needed to supplement clinical evidence on the overall benefits of ertapenem in this population.
BibTeX
@inproceedings{zhao2022effectiveness,
  author = {Ruiqiu Zhao and Xiaoru Long and Jiangxia Wang and Jing Zhu and Cong Liu and Tingting Shang and Zhenzhen Zhang and N Engels and Lynda Osadebe and Yue Kang and Jie Liu and Xiaodi Chen and Hongmei Xu},
  title = {{Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis}},
  booktitle = {Frontiers in Pediatrics},
  year = {2022},
  doi = {10.3389/fped.2022.982179},
}
Figure